(Q30316517)

17 June 2017

1 reference

title

Pharmacokinetic characteristics of therapeutic antibodies (English)

1 reference

17 June 2017

1 reference

Johannes Wohlrab

1

1 reference

17 June 2017

1 June 2015

1 reference

17 June 2017

1 reference

17 June 2017

13

1 reference

17 June 2017

6

1 reference

17 June 2017

530-534

1 reference

Biologics in dermatology: an integrated review

17 June 2017

1 reference

https://api.crossref.org/works/10.1111%2FDDG.12648_SUPPL

Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.12648_SUPPL

Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.12648_SUPPL

Clinical pharmacokinetics of therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.12648_SUPPL

The immunoglobulins: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.12648_SUPPL

Metabolic properties of IgG subclasses in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.12648_SUPPL

Development and production of commercial therapeutic monoclonal antibodies in Mammalian cell expression systems: an overview of the current upstream technologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.12648_SUPPL

Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.12648_SUPPL

Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.12648_SUPPL

Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.12648_SUPPL

Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.12648_SUPPL

High interstitial fluid pressure - an obstacle in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.12648_SUPPL

Vascular and interstitial barriers to delivery of therapeutic agents in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.12648_SUPPL

Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.12648_SUPPL

Renal filtration, transport, and metabolism of low-molecular-weight proteins: A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.12648_SUPPL

The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.12648_SUPPL

Immunogenicity of therapeutic proteins: clinical implications and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.12648_SUPPL

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.12648_SUPPL

Effect of Target Dynamics on Pharmacokinetics of a Novel Therapeutic Antibody against the Epidermal Growth Factor Receptor: Implications for the Mechanisms of Action

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FDDG.12648_SUPPL

21 January 2018

Identifiers

DOI

10.1111/DDG.12648_SUPPL

1 reference

17 June 2017

1 reference

PubMed ID

26018364